Laboratorio de Neuroinmunología y Neurooncología, Instituto Nacional de Neurología y Neurocirugía, Ciudad de México, México.
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):556-566. doi: 10.26355/eurrev_202101_24428.
A novel coronavirus named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a current outbreak of infection termed Coronavirus Disease 2019 (COVID-19) by the World Health Organization (WHO). COVID-19 is currently a global pandemic that may cause close to half a billion deaths around the world. Until now, there is no effective treatment for COVID-19. Quinacrine (Qx) has been used since the 1930s as preventive antimalarial compound. It is a recognized small molecule inhibitor of RNA virus replication, with known anti-prion activity, and identified as a potent Ebola virus inhibitor both in vitro and in vivo. Recently, Qx has showed anti-SARS-CoV-2 activity. Herein, we review the potential mechanisms associated with quinacrine as an antiviral compound.
一种名为严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）的新型冠状病毒是目前由世界卫生组织（WHO）命名的感染疾病，称为 2019 年冠状病毒病（COVID-19）。COVID-19 目前是一种全球大流行疾病，可能在全球范围内导致近 5 亿人死亡。到目前为止，还没有针对 COVID-19 的有效治疗方法。奎宁（Qx）自 20 世纪 30 年代以来一直被用作预防疟疾的化合物。它是一种公认的 RNA 病毒复制小分子抑制剂，具有已知的抗朊病毒活性，并被确定为体外和体内强效埃博拉病毒抑制剂。最近，Qx 显示出抗 SARS-CoV-2 的活性。在此，我们综述了奎宁作为抗病毒化合物的潜在作用机制。
